SEC Form 4 · accession 0001682852-26-000174
Moderna, Inc. · MRNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James M Mock
Officer — Chief Financial Officer
Period of report
Sep 10, 2026
Accepted (ET)
Sep 14, 2026 · 4:25 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001682852
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 10, 2026 | M | 19,836 | $30.96 | A | 94,211 | D | |
| Common Stock | Sep 10, 2026 | S | 19,836 | $134.49 | D | 74,375 | D | |
| Common Stock | Sep 10, 2026 | S | 15,000 | $134.49 | D | 59,375 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $30.96 | Sep 10, 2026 | M | 19,836 | D | — | Mar 1, 2035 | Common Stock | 19,836 | 43,642 | D |
Explanation of responses
- F1The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026.
- F225% of this option vested and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.